Long‐term follow‐up results of fertility sparing surgery in patients with epithelial ovarian cancer

Abstract

Conservative surgery in young women with epithelial ovarian cancer is an appropriate therapeutic option in patients who wish to preserve childbearing potential. Long-term follow-up results shows excellent overall survival and pregnancy results.

Fertility-sparing surgery for early stage epithelial ovarian cancer

“…I ovarian cancer by substage, histology and grade in young women Stage IA, non-CCC, G1 FSS is recommended for patients with Stage IA non-CCC and G1 disease. When data from 10 papers containing sufficient information about patients with Stage IA non-CCC and G1 disease (2,4,(10)(11)(12)(13)(16)(17)(18)(19) were combined, the recurrence-free rate was 93.4% (282/302), and the survival rate was 98.0% (296/302) ( Table 2). FSS not followed by adjuvant chemotherapy is adequate treatment for patients in this group because the absolute prognosis is good.…”

“…This difference may underlie the high recurrence rates reported by Schilder et al (12) Stage IA, CCC FSS followed by adjuvant chemotherapy may be considered for patients with Stage IA CCC. When data from six papers containing sufficient information about patients with Stage IA CCC (2,(10)(11)(12)16,30) were combined, although the recurrence-free rate was somewhat low, at 88.9% (24/27), the survival rate exceeded 90%, at 92.6% (25/27) ( Table 4). One patient was alive with cancer, and if this individual were to be added to the number of deaths, the survival rate would drop to slightly under 90%.…”

“…The only one of these six studies to describe lymphadenectomy as included in the surgical procedures was that of Anchezar (16), with the others listing biopsy, sampling or lymphadenectomy as options. The rate of lymph node metastasis in retroperitoneal, Stage I/II CCC identified by systematic lymphadenectomy has been reported as 29.4% (5/17) (31), and complete staging surgery is essential when performing FSS for CCC.…”

“…Some reports have evaluated CCC as a separate entity without grading it (2,5,30), whereas others have included it in G3 disease (4,(10)(11)(12)16). The proportion of epithelial ovarian cancer patients with CCC is rising in Japan, and it has recently been found to account for around 25% of all cases (32), whereas in North America and Europe, most ovarian cancer patients suffer from serous adenocarcinoma, with CCC patients accounting for only 1-12% of cases (33).…”

“…When data from seven papers containing sufficient information about patients with Stage IC CCC disease (2,(10)(11)(12)16,30,37) were combined, the recurrence-free rate was low, at 77.4% (24/31), although the survival rate exceeded 90%, at 90.3% (28/31) ( Table 7). Three Table 8.…”